We therefore decided to test the effects of dinaciclib on the expression of some of these genes and found a significant reduction in BCL-2, expression of which has been linked to platinum resistance in resistant ovarian cancer models (41). This evidence concerns the gene BCL2 and ovarian carcinoma.